1. Home
  2. GITS vs APM Comparison

GITS vs APM Comparison

Compare GITS & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GITS

Global Interactive Technologies Inc.

HOLD

Current Price

$1.54

Market Cap

6.5M

Sector

N/A

ML Signal

HOLD

Logo Aptorum Group Limited

APM

Aptorum Group Limited

HOLD

Current Price

$0.84

Market Cap

7.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GITS
APM
Founded
2018
2010
Country
South Korea
United Kingdom
Employees
5
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.5M
7.3M
IPO Year
N/A
2018

Fundamental Metrics

Financial Performance
Metric
GITS
APM
Price
$1.54
$0.84
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
145.4K
252.7K
Earning Date
05-19-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$0.65
52 Week High
$7.09
$4.47

Technical Indicators

Market Signals
Indicator
GITS
APM
Relative Strength Index (RSI) 41.25 44.35
Support Level $1.49 $0.74
Resistance Level $2.83 $0.93
Average True Range (ATR) 0.25 0.16
MACD -0.05 -0.02
Stochastic Oscillator 2.38 5.17

Price Performance

Historical Comparison
GITS
APM

About GITS Global Interactive Technologies Inc.

Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.

About APM Aptorum Group Limited

Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.

Share on Social Networks: